Blood test-guided immunotherapy for MSI-high colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colon cancer is a type called adenocarcinoma, mucinous, or signet-ring, and it is located at least 15 cm from the anal verge.
- Your tumor is MSI-high or dMMR (these are markers that may make immunotherapy more effective).
- You have not been treated with immunotherapy before (like PD-1 or CTLA-4 inhibitors).
- You are in generally good health (able to care for yourself, expected to live at least 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.